T. ļ.,

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY **PATENT APPLICATION TRANSMITTAL**

Attorney Docket No 021044-001210US First Inventor Hitoshi, Yasumichi, et al. SAK- MODULATION OF CELLULAR PROLIFERATION FOR

TREATMENT OF	CANCER	
Express Mail Label No.	EL 769971565 US	

			TREATMENT OF CANCER				0		
(Only for r	new nonprovisional applications under 37 C.F.R	. § 1.53(b))	Ex	rpress Mail	Label No.	EL 7	769971565 L	ıs	<u>م</u> _
	APPLICATION ELEMEN chapter 600 concerning design patent application Fee Transmittal Form (e.g., PTO/SB/17)	_		<u> </u>	RESS TO		Box Patent Washington	Commissioner for Patents Application n, DC 20231	5 U.S.
(Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages 56] (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention			Comments of the depression of the second of					JC67	
4. \(\sum \) [5. Oath or a. \(\sum \) b. \(\sum \)	Brief Summary of the Invention Brief Description of the Drawings (if filed) Detailed Description Claim(s) Abstract of the Disclosure Drawing(s) (35 U.S.C.113) [Total Sheet Declaration [Total Page Newly executed (original or copy) Copy from a prior application (37 CFR 1 (for a continuation/divisional with Box 18) DELETION OF INVENTOR(S)	es		9.	37 C.F.R (when the English 1 Information Statement Prelimina Return R (Should B Certified	.§3.73 ere is Fransl on Dis ont (IDS ary Ar eceip oe spe Copy	3(b)Statem an assigned ation Documesclosure S)/PTO-144 nendment t Postcard ecifically ite of Priority	Attorney Iment (if applicable) Copies of the Citations (MPEP 503) Immized) Document(s)	
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1 63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76				(if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent 17. Other:					
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No: Prior application information: Examiner Group Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.									
☑ Custon	ner Number or Bar Code Label	CORRESPO	••		, DICLOS				
Name		20 stom <u>e</u> r No. or A	350 Lttac		label here)		r 🗌 Co	rrespondence address be	low
Address				77					
City		State	T			Zip	Code		
Country	Telep	phone	1				Fax		
Name (Pr		_			No. (Attor	ney/A	lgent)	42,058	
Signature	mutte St	an		F			Date	December 21, 2001	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231. SF 1303391 v1

EXPRESS MAIL NO. EL 769971565 US

FEE TRANS	ATTTAL		Complete if Known					
		Application Number	Unassigned					
for FY 2001		Filing Date	December 21, 2001					
		First Named Inventor	Hitoshi, Yasumichi, et al.					
Patent fees are subject to annual revision.		Examiner Name	Unassigned					
	1	Group Art Unit	Unassigned					
TOTAL AMOUNT OF PAYMENT	(\$) 724	Attornov Docket No.	021044-001210119					

(b) 124			Attorney Docket No.			021044-00121005				
METHOD OF PAYMENT				FEE CALCULATION (continued)			ALCULATION (continued)			
The Commissioner is hereby authorized to charge indicated foes and gradit any over a property to				3. ADDITIONAL FEES						
indicated lees and credit any over payments to					Entity		Entity			
Deposit Account Number		Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid			
		105	130	205	65	Surcharge - late filing fee or oath	, alu			
				127	50	227	25	Surcharge - late provisional filing fee		
Deposit								or cover sheet.		
Account Name	Townsend and	d Townsend and	Crew LLP	139	130	139	130	Non-English specification		
	Additional Equ	Dogwised.		147	2,520	147	2,520	For filing a request for reexamination		
☐ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 ☐ Applicant claims small entity status.			112	920*	112	920*	Requesting publication of SIR prior to Examiner action			
See 37 CFR	1 27	y status.		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
2. 🔲 Payment I	Enclosed:			115	110	215	55	Extension for reply within first month		
☐ Check ☐ Credit card ☐ Money ☐ Other Order			116	400	216	200	Extension for reply within second month			
-	EEE C			117	920	217	460	Extension for reply within third month		
FEE CALCULATION 1. BASIC FILING FEE				118	1,440	218	720	Extension for reply within fourth month		
Large Entity Sm	all Entity			128	1,960	228	980	Extension for reply within fifth month		
Fee Fee Fee		Fee Description		119	320	219	160	Notice of Appeal		
Code (\$) Cod 101 740 201		1.000	Fee Paid	120	320	220	160	Filing a brief in support of an appeal	*****	
		Utility filing fee	370	121	280	221	140	Request for oral hearing		
106 330 206 107 510 207		Design filing fee Plant filing fee		138	1,510	138	1,510	Petition to institute a public use proceeding		
108 740 208	370	Reissue filing fee		140	110	240	55	Petition to revive – unavoidable		
114 160 214 80 Provisional filing fee		141	1,280	241	640	Petition to revive – unintentional				
	0.10-0-1			142	1,280	242	640	Utility issue fee (or reissue)		
	SUBTOTAL	L (1)	(\$)370	143	460	243	230	Design issue fee		
2. EXTRA CLAIM F	EES			144	620	244	310	Plant issue fee		
			e from Fee	122	130	122	130	Petitions to the Commissioner		
Total Claims 50		Claims bel	ow Paid 9 = \$270	123	50	123	50	Petitions related to provisional applications		
Independent Claims 5	-3** = 2	2 X \$	42 = \$84	126	180	126	180	Submission of Information Disclosure Stmt		
Multiple Dependent	_	×	=	581	40	581	40	Recording each patent assignment per property (times number of properties)		
Large Entity Sr Fee Fee Fe	mall Entity ee Fee			146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))		
***	ode (\$) 03 9	Fee Descript Claims in exc		149	740	249	370	For each additional invention to be		
	02 42		dependent claims in excess of 3					examined (37 CFR § 1.129(b))		
104 280 20	04 140	· ·	ndent claim, if not paid	179	740	279	370	Request for Continued Examination (RCE)		
109 84 20	09 42	** Poissus independent eleime avec			900	169	900 Request for expedited examination of a design application			
110 18 210 9 ** Reissue claims in excess of 20 and over original patent			Other fee (specify)							
SUBTOTAL (2) (\$)354			The Commissioner is authorized to charge any additional fees to the above noted Deposit Account.							
				*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)0						
**or number previously paid, if greater; For Reissues, see above										

SUBMITTED BY				Co	omplete (if applicable)	_
Name (Print/Type)	Annette S. Parent	Registration No. (Attorney/Agent)	42,058	Telephone	415-576-0200	
Signature	annet	tes/Parent		Date	December 21, 2001	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.